These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38246910)

  • 21. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive PD-L1 quantification using [
    Mishra A; Gupta K; Kumar D; Lofland G; Sharma AK; Solnes LB; Rowe SP; Forde PM; Pomper MG; Gabrielson EW; Nimmagadda S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical and first-in-human evaluation of
    Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of [
    Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
    Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
    Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
    Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
    Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
    Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
    J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising potential of a
    Lv G; Miao Y; Chen Y; Lu C; Wang X; Xie M; Qiu L; Lin J
    Bioorg Chem; 2021 Oct; 115():105294. PubMed ID: 34426150
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
    Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
    Mishra A; Kumar D; Gupta K; Lofland G; Sharma AK; Banka DS; Hobbs RF; Dannals RF; Rowe SP; Gabrielson E; Nimmagadda S
    Clin Cancer Res; 2023 Feb; 29(3):581-591. PubMed ID: 36449662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
    Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
    Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.
    Jouini N; Cardinale J; Mindt TL
    ChemMedChem; 2022 Jun; 17(12):e202200091. PubMed ID: 35388635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Preclinical Evaluation of [
    Huang Y; Li C; Li Z; Wang Q; Huang S; Liu Q; Liang Y
    Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
    Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
    Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging.
    Guo Z; Zhu L; Xu W; Luo X; Chen H; Li X; Zuo C
    Biochem Biophys Res Commun; 2023 Sep; 673():23-28. PubMed ID: 37354656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
    Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
    J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.